EDIT · Healthcare
Editas Medicine Inc
15/100
Smart-money confidence1 of 3 sources positive
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
20
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$453M
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About EDITAS MEDICINE INC
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research…
Who's behind the signal
Every informed buyer we can see on EDIT, across all three feeds.
Hedge funds · 4
D.E. Shaw & Co
Increased +75%
AQR Capital Management
Increased +113%
Point72 (Steve Cohen)
Decreased −84%
Citadel Advisors
Decreased −19%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Congressional trades · 12 on record
Disclosures from 2017-10-19 to 2021-04-14
The newest disclosure we hold for this stock is 2021-04-14.
That is the end of our data, not necessarily the end of the trading — our
bulk STOCK Act archive stops there and newer filings arrive through a
separate live feed. Treat the absence of recent rows as “not covered”,
not as “no trades”.
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2021-04-14 | Donald S. Beyer, Jr. · D-VA | House | Sold | $1,001 - $15,000 |
| 2021-03-02 | Donald S. Beyer, Jr. · D-VA | House | Sold | $1,001 - $15,000 |
| 2020-11-17 | Donald S. Beyer, Jr. · D-VA | House | Bought | $1,001 - $15,000 |
| 2020-05-01 | Donald S. Beyer, Jr. · D-VA | House | Sold | $1,001 - $15,000 |
| 2020-04-27 | Donald S. Beyer, Jr. · D-VA | House | Sold | $1,001 - $15,000 |
| 2020-01-27 | Donald S. Beyer, Jr. · D-VA | House | Bought | $1,001 - $15,000 |
| 2020-01-09 | Donald S. Beyer, Jr. · D-VA | House | Bought | $1,001 - $15,000 |
| 2019-12-23 | Donald S. Beyer, Jr. · D-VA | House | Bought | $1,001 - $15,000 |
| 2019-06-04 | Donna E. Shalala · D-FL | House | Sold | $1,001 - $15,000 |
| 2019-03-06 | Donna E. Shalala · D-FL | House | Bought | $1,001 - $15,000 |
Show the other 2
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2019-02-04 | James M. Inhofe · R-OK | Senate | Sold | $15,001 - $50,000 |
| 2017-10-19 | James M. Inhofe · R-OK | Senate | Bought | $15,001 - $50,000 |
Not a model pick — but on our radar.
EDITAS MEDICINE INC isn't in the top-10 model right now, but 4 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
4
Investors
0
New positions
2
Increasing
2
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+75%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+113%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
−84%
0.0% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−19%
0.0% of Citadel Advisors's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to EDITAS MEDICINE INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell EDITAS MEDICINE INC or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订